In a study by He et al., 2016, six gene mutations in cfDNA were shared between healthy controls and NSCLC patients, however, mutations in TP53 as well as in other genes were exclusively found in cancer patients [26], suggesting the mutation pattern may differ between cancer-affected and cancer-free individuals. This evidence concerns the gene TP53 and non-small cell lung carcinoma.